NCT02362997已完成2 期
A Phase 2 Study of Pembrolizumab (MK-3475) After Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma and, Diffuse Large B Cell Lymphoma and T- Cell Non-Hodgkin Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 82
- 试验地点
- 6
- 主要终点
- Progression-free Survival After ASCT
研究概览
简要总结
This phase II study is designed to determine the clinical efficacy of PD-1 blockade, using the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475), administered as consolidation therapy after autologous stem cell transplant (ASCT), in patients with relapsed or refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL), classical Hodgkin Lymphoma (cHL) or peripheral T-cell lymphoma (PTCL) in 1st remission.
详细描述
Pembrolizumab is an antibody drug that blocks a molecule called PD-1. PD-1 is a receptor molecule on the surface of immune cells that can be used to turn off the immune response. Some cancers use this as a way to turn off the immune response against them. Blocking PD-1 with pembrolizumabmay restore an effective immune attack against the lymphoma cells.
On this study, patients who undergo ASCT for R/R cHL, DLBCL or PTCL in 1st remission will receive pembrolizumab at a dose of 200mg intravenously every 3 weeks for up to 8 cycles, beginning within a few weeks of ASCT.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed diagnosis with review of the diagnostic pathology specimen at one of the participating institutions. Eligible histologies are: Arm A: Diffuse large B cell lymphoma; patients with a prior history of indolent B-cell NHL are eligible, as long as they have histologically confirmed DLBCL prior to their pre-transplant salvage treatment. Patients with mediastinal large B cell lymphoma are also eligible.
- •Arm B: Classical Hodgkin lymphoma (patients with nodular lymphocyte predominant Hodgkin lymphoma [NLPHL] are NOT eligible) Arm C: Peripheral T cell lymphoma - eligible subtypes will include PTCL, NOS; AITL; and ALK-negative ALCL. Patients with other PTCL histologies, including ALK-positive PTCL, and cutaneous T-cell lymphoma will not be eligible..
- •Age ≥ 18 at the time of enrollment.
- •For arms A and B, participants must have relapsed after or been refractory to first-line chemotherapy, i.e., they must have failed to achieve CR after first-line therapy or must have relapsed subsequently if they achieved CR. For arm C, participants will be eligible if transplant is performed as consolidation of first remission (partial or complete).
- •Participants must be planning to receive or have received autologous stem cell transplantation. Participants must have chemosensitive disease prior to ASCT, defined as achieving at least a partial remission (as determined with PET imaging) to salvage treatment. Participants with cHL or DLBCL (arms A and B) transplanted in 1st remission after only one line of treatment are not eligible. Participants with PTCL (arm C) transplanted beyond 1st remission are also not eligible.
- •No more than 1 line of anthracycline-containing chemotherapy prior to ASCT, and no more than 3 lines of therapy total prior to ASCT for arms A and B; no more than 1 line of therapy prior to ASCT for arm C.
- •Participants cannot have received any anti-neoplastic therapy (including radiotherapy, chemotherapy or immunotherapy) after ASCT
- •Participants must have had PET-CT for restaging after salvage therapy and before ASCT.
- •Participants must begin study treatment no later than 21 days from the post-ASCT discharge. Additionally, they must have recovered from ASCT toxicities at the time of first study treatment.
- •ECOG performance status ≤2
- •Participants must have normal organ and marrow function as defined below:
- •absolute neutrophil count ≥ 1,000/mcL
- •platelets ≥ 50,000/mcL
- •Hemoglobin ≥ 8 g/dl
- •total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN), or direct bilirubin ≤ ULN in patients with Gilbert's syndrome
- •AST(SGOT)/ALT(SGPT) ≤ 2.5 × ULN
- •Creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 60 mL/min/1.73 m2
- •Resting and ambulatory oxygen saturation ≥ 94% on room air
- •FEV1 and DLCO (adjusted for Hemoglobin) ≥ 50% predicted
- •Willigness to use contraception
- •Ability to understand and the willingness to sign a written informed consent document.
排除标准
- •Participants who are receiving any other investigational agents after ASCT.
- •Participants with active CNS involvement are excluded.
- •History of or active autoimmune disease, or other syndrome that requires systemic steroids or autoimmune agents. Participants with vitiligo, resolved childhood asthma or atopy, hypothyroidism, or Sjogren's syndrome, as well as participants requiring only intranasal steroids, intermittent use of bronchodilators, local steroid injections, or physiologic replacement doses of prednisone (≤ 10 mg/d) are not excluded from this study.
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab. Prior hypersensitivity reactions to anti-CD20 therapy or anti-CD30 therapy is not an exclusion criterion.
- •Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.
- •Receipt of > 600 mg/m2 total dose of BCNU with prior treatments including transplant conditioning regimen.
- •Uncontrolled illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements or pose excess risk to the participant in the opinion of the treating clinician..
- •Pregnant or lactating women.
- •HIV-positive.
- •Participants with active viral hepatitis (positive HepB sAg, positive HepB core Ab with positive HepB viral load, or positive HepC antibody with positive HepC viral load).
- •Receipt of a live vaccine within 30 days of the start of treatment. Examples are measles, mumps, rubella, varicella, yellow fever, rabies, BCG, oral polio vaccine, and oral typhoid vaccine.
- •Prior treatment with an anti PD-1, anti PD-L1, or anti CTLA-4 agent. Participants who entered clinical remission with one of those agents and proceeded to ASCT without intervening relapse may be eligible after discussion with the Study Chair. Note that for patients who enter remission with checkpoint blockade therapy, this will not count towards the 3 lines of prior therapy.
研究组 & 干预措施
Peripheral T cell lymphoma
Experimental
Pembrolizumab 200mg IV every 3 weeks up to 8 cycles
干预措施: Pembrolizumab (Drug)
Classical Hodgkin lymphoma
Experimental
Pembrolizumab 200mg IV every 3 weeks up to 8 cycles
干预措施: Pembrolizumab (Drug)
Diffuse large B cell lymphoma
Experimental
Pembrolizumab 200mg IV every 3 weeks up to 8 cycles
干预措施: Pembrolizumab (Drug)
结局指标
主要结局
Progression-free Survival After ASCT
时间窗: 18 Months
Proportion of patients alive and disease-free 18 months from autologous stem cell transplantation (ASCT). Progression criteria are per Lugano 2014 criteria. All patients receiving any amount of protocol treatment. Patients who have progressed or lost to follow-up prior to 18 months are counted as failures; only patients followed and progression-free for at least 18 months are counted as successes.
次要结局
- Relapse(18 Months)
- Safety and Tolerability Assessed by CTCAE v4 Grade 2 and Above Toxicity Related to Study Treatment(6 months)
- Progression-free Survival(18 months)
- Overall Survival(18 Months)
- Response Rate to Pembrolizumab(18 months)
研究者
Reid Merryman, MD
Principal Investigator
Dana-Farber Cancer Institute
研究点 (6)
Loading locations...
相似试验
已完成
2 期
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin LymphomasRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Lymphoplasmacytic LymphomaRecurrent Marginal Zone LymphomaRecurrent Nodal Marginal Zone LymphomaRecurrent Small Lymphocytic LymphomaRecurrent Splenic Marginal Zone LymphomaRecurrent Waldenstrom MacroglobulinemiaRefractory B-Cell Non-Hodgkin LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueRefractory Follicular LymphomaRefractory Lymphoplasmacytic LymphomaRefractory Nodal Marginal Zone LymphomaRefractory Small Lymphocytic LymphomaRefractory Splenic Marginal Zone LymphomaRefractory Waldenstrom MacroglobulinemiaRichter SyndromeWaldenstrom MacroglobulinemiaNCT02332980Mayo Clinic65
进行中（未招募）
2 期
Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior ChemotherapyEdemaErythemaEstrogen Receptor NegativeHER2/Neu NegativePeau d'OrangeProgesterone Receptor NegativeRecurrent Inflammatory Breast CarcinomaStage IV Inflammatory Breast CarcinomaTriple-Negative Breast CarcinomaNCT02411656M.D. Anderson Cancer Center71
进行中（未招募）
2 期
Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by SurgeryDesmoplastic MelanomaNCT02775851National Cancer Institute (NCI)57
已完成
1 期
Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung CancerStage II Non-Small Cell Lung CancerStage IIIA Non-Small Cell Lung CancerStage IIIB Non-Small Cell Lung CancerNCT02621398Rutgers, The State University of New Jersey23
已完成
2 期
Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaNCT04387227University of Washington22